IBDEI0MW ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11210,0)
 ;;=203.02^^64^694^104
 ;;^UTILITY(U,$J,358.3,11210,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11210,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,11210,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,11210,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,11211,0)
 ;;=204.02^^64^694^2
 ;;^UTILITY(U,$J,358.3,11211,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11211,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,11211,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,11211,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,11212,0)
 ;;=204.12^^64^694^17
 ;;^UTILITY(U,$J,358.3,11212,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11212,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,11212,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,11212,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,11213,0)
 ;;=204.20^^64^694^114
 ;;^UTILITY(U,$J,358.3,11213,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11213,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,11213,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,11213,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,11214,0)
 ;;=204.21^^64^694^116
 ;;^UTILITY(U,$J,358.3,11214,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11214,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,11214,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,11214,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,11215,0)
 ;;=204.22^^64^694^115
 ;;^UTILITY(U,$J,358.3,11215,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11215,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,11215,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,11215,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,11216,0)
 ;;=205.02^^64^694^5
 ;;^UTILITY(U,$J,358.3,11216,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11216,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,11216,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,11216,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,11217,0)
 ;;=205.12^^64^694^20
 ;;^UTILITY(U,$J,358.3,11217,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11217,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,11217,1,5,0)
 ;;=5^CML,In Relapse
 ;;^UTILITY(U,$J,358.3,11217,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,11218,0)
 ;;=284.81^^64^694^14
 ;;^UTILITY(U,$J,358.3,11218,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11218,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,11218,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,11218,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,11219,0)
 ;;=284.89^^64^694^13
 ;;^UTILITY(U,$J,358.3,11219,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11219,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,11219,1,5,0)
 ;;=5^Aplastic Anemia d/t Chronic Disease
 ;;^UTILITY(U,$J,358.3,11219,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,11220,0)
 ;;=289.84^^64^694^119
 ;;^UTILITY(U,$J,358.3,11220,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11220,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,11220,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,11220,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,11221,0)
 ;;=V10.91^^64^694^67
 ;;^UTILITY(U,$J,358.3,11221,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11221,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,11221,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,11221,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,11222,0)
 ;;=V10.91^^64^694^66
 ;;^UTILITY(U,$J,358.3,11222,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11222,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,11222,1,5,0)
 ;;=5^H/O Malignant Neoplasm,Unspec
 ;;^UTILITY(U,$J,358.3,11222,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,11223,0)
 ;;=465.9^^64^695^70
 ;;^UTILITY(U,$J,358.3,11223,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11223,1,4,0)
 ;;=4^465.9
